5 hours ago
1
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, making it the country’s first amyloid-targeting treatment available for the memory-robbing disease following a setback for a rival Alzheimer’s drug from Biogen (NASDAQ:BIIB).
The
English (US) ·